Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.
The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.
